Public Radio East serves Eastern North Carolina by providing news, fine arts, and informational programming that challenges, stimulates, educates, and entertains an intellectually curious audience.

© 2026 Public Radio East

Public Radio East
800 College Court
New Bern, NC 28562

EIN 56-1802728
Public Radio For Eastern North Carolina 89.3 WTEB New Bern 88.5 WZNB New Bern 91.5 WBJD Atlantic Beach 90.3 WKNS Kinston 89.9 W210CF Greenville
Donate
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Join our team! Public Radio East is hiring a Financial & Development Associate.

Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

NPR | By Sydney Lupkin,
Steve Inskeep
Published May 22, 2026 at 4:44 AM EDT

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Copyright 2026 NPR
Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
See stories by Sydney Lupkin
Steve Inskeep
Steve Inskeep is a host of NPR's Morning Edition, as well as NPR's morning news podcast Up First.
See stories by Steve Inskeep